Pfizer’s PFE stock has risen 5.9% in the past three months. The stock has started to show a consistent increase, with some ...

Pfizer only picked up an accelerated approval from the FDA for its Braftovi-based combination regimen for colorectal cancer last month, and it already has survival data that could see that ...

We recently compiled a list of the 10 Most Undervalued US Stocks to Buy According to Hedge Funds. In this article, we are ...

Pfizer (PFE) announced positive topline results from the progression-free survival – PFS – analysis of the Phase 3 BREAKWATER study of Braftovi – encorafenib – in combination with ...

PFE offers a 6.73% dividend yield and growth potential, driven by strategic acquisitions, R&D, and discounted valuations.

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Pfizer's EPS and revenue beat my expectations ... mainly due to increased demand for its antibody-drug-conjugates, Xtandi, Elrexfio, Braftovi/Mektovi, and Elrexfio, which is a BCMA/CD3 bispecific ...

The all-or-nothing strategy has landed the ‘pride of the pharmaceutical industry' in a situation that deteriorated rapidly.

Pfizer reported fourth-quarter 2024 adjusted ... driven by strong contributions from Padcev, Xtandi, Lorbrena and Braftovi/Mektovi. In Primary Care, alliance revenues and direct sales from Bristol ...